^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

LY9 expression

i
Other names: LY9, Lymphocyte Antigen 9, SLAMF3, Signaling Lymphocytic Activation Molecule 3, T-Lymphocyte Surface Antigen Ly-9, Cell Surface Molecule Ly-9, SLAM Family Member 3, CD229, Hly9, MLY9, CD229 Antigen
Entrez ID:
Related biomarkers:
5ms
Single Cell RNA Sequencing of Sequential Samples before and after BCMA-Directed CAR-T Reveal Features Associated with Non-Durable Response, Exhausted T-Cells and Decreased Expression of Genes Encoding Key Surface Targets in Particular in Patients with Extramedullary Disease (ASH 2023)
Conclusion These data highlight the pre-treatment features of both tumor and T-cell that can pre-dispose real-world patients with RRMM to early relapse after anti-BCMA CAR-T, notably pre-existing T-cell exhaustion, and the presence of highly proliferative plasma cells with underlying resistance mechanisms, including downregulation of several known immunotherapy targets, especially in those with co-existing EMD. Ciara L Freeman, Xiaohong Zhao & Mark B Meads contributed equally
Clinical • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • IL6 (Interleukin 6) • CD44 (CD44 Molecule) • LY9 (Lymphocyte Antigen 9) • SDC1 (Syndecan 1) • PRDM1 (PR/SET Domain 1) • CD48 (CD48 Molecule) • XBP1 (X-box-binding protein 1)
|
LY9 expression • CD44 expression
8ms
Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicity. (PubMed, Sci Transl Med)
We identified a CD229 CAR binding domain with micromolar affinity that, when combined with overexpression of c-Jun, confers antitumor activity comparable to parental CD229 CAR T cells but lacks the parental cells' cytotoxic activity toward healthy lymphocytes in vitro and in vivo. The results represent a promising strategy to improve the efficacy and safety of CAR T cell therapy that requires clinical validation.
Journal • CAR T-Cell Therapy
|
LY9 (Lymphocyte Antigen 9) • JUN (Jun proto-oncogene)
|
LY9 expression
|
CD229 CAR T
11ms
AUTOMATED SEPARATION OF CELL CLUSTERS PROVIDES AN EASY AND ACCURATE STRATEGY FOR THE ANALYSIS OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MIELOMA IN SINGLE 11-COLORS FLOW CYTOMETRY COMBINATION. (EHA 2023)
The described methodology is simple and allows the objective identification of residual populations in a single tube, no need to merge files or calculate data for the analysis. All the selected markers are necessary to maximize the discriminative potential of the technique. Larger studies are required in order to find out if the increase in CD28 expression or the appearance of different subclones in the residual populations may be related to chemoresistance and clonal selection phenomena.
IO biomarker • Minimal residual disease
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • LY9 (Lymphocyte Antigen 9) • NCAM1 (Neural cell adhesion molecule 1) • CD28 (CD28 Molecule) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
|
CD38 expression • LY9 expression
1year
BCMA AND CD229 DUAL-TARGETED CAR T CELL EFFECTIVELY CONTROLS MULTIPLE MYELOMA WITH LOSS OF BCMA EXPRESSION (EBMT 2023)
At our institution, we have developed an academic BCMA-BBζ CART product (ARI2h; NCT04309981) for relapsed/refractory MM patients with encouraging results... This is the first bispecific BCMA/CD229 CART cell that adequately controls BCMA-expressing and non-expressing myeloma cells. This approach could mitigate disease escape due to biallelic loss of BCMA.
CAR T-Cell Therapy • IO biomarker
|
LY9 (Lymphocyte Antigen 9)
|
LY9 expression
|
cesnicabtagene autoleucel (ARI0002h)
over1year
CD229 interacts with RASAL3 to activate RAS/ERK pathway in multiple myeloma proliferation. (PubMed, Aging (Albany NY))
Additionally, we developed a co-culture method combined with the immunofluorescence assay to confirm that intercellular tyrosine phosphorylation mediated self-activation of CD229 to activate RAS/ERK signaling pathway via interacting with RASAL3. Taken together, these findings not only demonstrate the oncogenic role of CD229 in MM cell proliferation, but also illustrate the potential of CD229 as a promising therapeutic target for MM treatment.
Journal • IO biomarker
|
LY9 (Lymphocyte Antigen 9)
|
LY9 expression
over1year
Utility of CD229 as novel marker in measurable residual disease assessment in multiple myeloma-An evidence-based approach. (PubMed, Int J Lab Hematol)
CD229 can be used for the identification of PC and due to relatively homogenous expression; it can be used as a suitable marker for targeted therapies. However, precise discrimination of NPC from APC cannot be reliably achieved with CD229, limiting its utility as a useful marker of diagnostic relevance and MRD assessment in MM.
Journal • IO biomarker
|
LY9 (Lymphocyte Antigen 9) • SDC1 (Syndecan 1)
|
CD38 expression • LY9 expression
over1year
MM-267 Expression of CD229 on Bone Marrow Cellular Compartment and Its Relevance in Multiple Myeloma. (PubMed, Clin Lymphoma Myeloma Leuk)
This study shows that CD229 can be used for the identification of PCs and due to relatively homogenous expression; it can be used as a suitable marker for targeted therapies. However, CD229 is not a satisfactory marker for discriminating NPC from APC, thus limiting its ability as a useful marker of diagnostic relevance and residual disease assessment in MM cases.
Journal • IO biomarker
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • LY9 (Lymphocyte Antigen 9) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
|
CD38 expression • LY9 expression
over1year
Expression of CD229 on Bone Marrow Cellular Compartment and Its Relevance in Multiple Myeloma (SOHO 2022)
This study shows that CD229 can be used for the identifi cation of PCs and due to relatively homogenous expression; it can be used as a suitable marker for targeted therapies. However, CD229 is not a satisfactory marker for discriminating NPC from APC, thus limiting its ability as a useful marker of diagnostic relevance and residual disease assessment in MM cases.
IO biomarker
|
KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • LY9 (Lymphocyte Antigen 9) • NCAM1 (Neural cell adhesion molecule 1) • SDC1 (Syndecan 1) • CD27 (CD27 Molecule) • CD81 (CD81 Molecule)
|
CD38 expression • LY9 expression
almost2years
Upregulation of CXCL1 and LY9 contributes to BRCAness in ovarian cancer and mediates response to PARPi and immune checkpoint blockade. (PubMed, Br J Cancer)
In conclusion, 2-GPS could robustly predict BRCAness OvCa at the individual level and extend the population who may benefit from PARP inhibitors.
Journal • Checkpoint inhibition • BRCA Biomarker • PARP Biomarker
|
BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • LY9 (Lymphocyte Antigen 9) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
|
BRCA2 mutation • BRCA1 mutation • HRD • HRD + BRCA1 mutation • LY9 expression
|
Lynparza (olaparib) • cisplatin • mitomycin
almost2years
CD229 (Ly9) a Novel Biomarker for B-Cell Malignancies and Multiple Myeloma. (PubMed, Cancers (Basel))
Serum levels of soluble CD229 (sCD229) at the time of diagnosis in MM patients could be useful as a prognostic biomarker. In conclusion, our results indicate that CD229 represents not only a useful biomarker but also an attractive therapeutic target.
Journal
|
LY9 (Lymphocyte Antigen 9)
|
LY9 expression
almost2years
Engineering anti-CD229 CAR T cell selectivity for multiple myeloma (IMMUNOLOGY 2022)
Using a novel unbiased mutagenesis approach, we show that generation of minimally altered low affinity variants from existing antibodies is feasible and results in binders with substantially reduced affinity. Low affinity variants show increased selectivity eliminating a key liability of CD229 CAR T cells.
CAR T-Cell Therapy
|
LY9 (Lymphocyte Antigen 9)
|
LY9 expression
over2years
CD229 CAR T Cell Therapy for the Treatment of Relapsed B Cell Lymphoma (ASH 2021)
Finally, CD229 CAR T cells are effective against primary CLL cells from patients that have relapsed from CD19 CAR T cell therapy and do no exhibit antigen loss by trogocytosis. Taken together, these data suggest that CD229 CAR T cell therapy may be a promising option to address the poor outcomes for patients with relapsed B cell lymphoma.
CAR T-Cell Therapy
|
CD19 (CD19 Molecule) • IFNG (Interferon, gamma) • IL2 (Interleukin 2) • LY9 (Lymphocyte Antigen 9)
|
CD19 expression • LY9 expression
|
CD229 CAR T